Monograph

C09AA10 - Trandolapril

Propably not porphyrinogenic

Rationale

Presystemic metabolism. To a large part not metabolised. No data pointing to CYP-interaction. Two references stating (probable) non-porphyrinogenicity.

Chemical description

Prodrug, hydrolyzed to trandoprilate, ACE-inhibitor. Low bioavailability (4-14%) due to incomplete absorbtion and presystemic metabolism. 36-95% of the aborbed dose is excreted in unchanged form by the kidneys. South African list: use with care. French list: authorized.

Therapeutic characteristics

Less common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and obstipation.

IPNet drug reports

Uneventful use reported in 3 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C09A / C09AA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames